Study on the efficacy and safety of three different doses of Lais Ambrosia tablets in patients with allergic rhinoconjunctivitis to pollen of Ambrosia [ Studio sull'efficacia e la sicurezza di tre diversi dosaggi di Lais Ambrosia compresse in pazienti con rinocongiuntivite allergica al polline di Ambrosia]

Trial Profile

Study on the efficacy and safety of three different doses of Lais Ambrosia tablets in patients with allergic rhinoconjunctivitis to pollen of Ambrosia [ Studio sull'efficacia e la sicurezza di tre diversi dosaggi di Lais Ambrosia compresse in pazienti con rinocongiuntivite allergica al polline di Ambrosia]

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2013

At a glance

  • Drugs Ragweed allergy immunotherapy (Primary)
  • Indications Allergic rhinoconjunctivitis; Ragweed pollen hypersensitivity
  • Focus Therapeutic Use
  • Sponsors Lofarma S.p.A
  • Most Recent Events

    • 05 Oct 2013 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
    • 14 Nov 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top